32results about How to "Promoting transcription" patented technology

The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.

The invention provides, among other things, regulated polymerase III expression systems and related compositions. The invention provides, in part, expression systems in which the expression is inducible, and systems which express inhibitory RNA molecules, such as hairpin RNA molecules. The invention also provides related methods, such as methods of inhibiting expression of a gene.

The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes.

The present invention relates to the field of ischemic retinopathies. More specifically, the present invention provides methods and compositions useful for treating ischemic retinopathies including diabetic macular edema (DME). The present invention also provides methods for treating ischemic retinopathy comprising the step of administering to a subject diagnosed with ischemic retinopathy an effective amount of an ANGPTL4 antagonist.

Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.

It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.

Methods and systems for multi level quality checking of transcripts are disclosed. The method includes the steps of searching subsets of metadata associated with the transcripts, identifying a group of transcripts having at least one particular subset of metadata, selecting a number of transcripts from the group of identified transcripts corresponding to a predetermined percentage, identifying a group of correctionists having a proper set of characteristics to correct the selected transcripts by matching the identified subsets of metadata associated with the transcripts with characteristics of correctionists, providing the transcripts and any voice files from which the transcripts derive to the selected correctionists, and, following correction, updating the subsets of metadata associated with the transcripts to include subsets of metadata pertaining to the voice files from which the transcripts were derived, any transcriptionist who transcribed the transcripts, or any correctionist who corrected the transcripts.

The present invention relates to the treatment of breast cancer which is estrogen receptor positive (ER⁺) and/or human epidermal growth factor receptor 2 positive (HER2) and/or progesterone receptor positive (PR) and/or facilitates chromatin transcription positive (FACT+) with a curaxin, including curaxin 137. The present invention also pertains to a method of identifying a subject who has a breast cancer tumor and is likely to respond to treatment with a curaxin.

Novel microorganisms are provided that efficiently convert xylose (or xylulose) alone or in combination with a carbon substrate to produce xylitol. In certain embodiments, E. coli are engineered to include a mutant crp gene as well as deletion of the xylB gene. The microorganisms of the invention are particularly advantageous because they serve as biocatalysts for the efficient and scalable conversion of biomass-derived sugars into xylitol.

Provided are compositions, libraries, and methods for the synthesis of transcripts that can be processed to produce nucleic acid capture probes. Also provided methods for using such nucleic acid capture probes in a variety of downstream applications, including, e.g., determining the sequence of an exon-exon junction.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

The object of the present invention is to, by analyzing PPR proteins that act to bind to DNA with a prediction that RNA recognition rules of PPR motifs can also be used for recognition of DNA, find a PPR protein showing such a characteristic. According to the present invention, it was revealed that, with a protein that can bind in a DNA base-selective manner or a DNA base sequence-specific manner, which contains one or more, preferably 2 to 30, more preferably 5 to 25, most preferably 9 to 15, of PPR motifs having a structure of the following formula 1 (wherein, in the formula 1, Helix A is a part that can form an α-helix structure; X does not exist, or is a part consisting of 1 to 9 amino acids; Helix B is a part that can form an α-helix structure; and L is a part consisting of 2 to 7 amino acids), and having a specific combination of amino acids corresponding to a DNA base or DNA base sequence as amino acids of three positions of No. 1 A.A., No. 4 A.A., in Helix A of the formula 1 and No. “ii” (-2) A.A. contained in L of the formula 1, the aforementioned object could be achieved.

(Helix A)-X-(Helix B)-L  (Formula 1)

The present invention provides methods for producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope, using neuraminidase (NA) derived from Gram-positive bacteria. The methods comprise the steps of culturing cells producing a viral vector in the presence of an NA from Gram-positive bacteria, and recovering the produced virus. The methods of this invention enable the production of high titer virus at high cost performance. Such a viral vector is capable of transferring genes at high efficiency into cells such as blood cells and hematopoietic cells, including hematopoietic stem cells, and mucous cells including mucoepithelial cells, those not amenable to gene transfer by conventional methods, and therefore should be useful as a vector for gene therapy.

The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as TNF-α, IL-1β, NOS2 and IL-6, and also can inhibit the activity or production of Th17 and increase the activity or production of a regulatory T cell (Treg). Thus, it is expected that the thiourea derivative may be usefully used in a pharmaceutical composition, a health food composition, etc. for the prevention, improvement or treatment of various autoimmune diseases including rheumatoid arthritis.

Disclosed are systems and methods that enable robust, universal authentication and network access control capabilities for networks having a variety of computing device types and end users that access and operate on the network. The systems permit verification of end user identity, confirmation that computing devices have sufficient resources to reliably operate on the network, and configuration of computing devices with required software applications. The systems and methods further enable real-time, intelligent monitoring of the tasks and functions performed by system end users. The systems provide an immersive experience that allows end users to teleport into the environment of other end users, including viewing another end user's computer desktop, listening to ongoing telephone conversations, viewing and analyzing contemporaneous images or video of an end user and the end user's work environment, and interacting with the end user to provide precision coaching and assistance.

Modulation of the activity of glucocorticoid inducible kinase SGK1 in pancreatic islet cells restores insulin release. Also disclosed are methods and compounds useful for the treatment of glucocorticoid induced diabetes mellitus type-2.

The present invention relates to a use of CBX4 as a target for activation of HIV-1 latent infection. The present invention found by research that, inhibiting CBX4 causes a good ability for activation of HIV-1 latent, a knockdown of CBX4 can effectively promote a transcription of LTR of HIV-1; and afterwards the present invention has found that, by the knockdown of CBX4 in a J-lat 10.6 cell model of HIV-1 latent infection, GFP gene expression is up-regulated, and HIV-1 can be effectively activated. An overexpression of the CBX4 protein in TZM-bl cells can effectively decrease a transcriptional activity of LTR of HIV-1. It is found by further detection that, decreased expression of CBX4 protein will reduce a degree of enrichment of H3K9 trimethylation and H3K27 trimethylation of LTR of HIV-1, thereby activating HIV-1 latent infection.

The invention relates to methods for generating a recombinant adenovirus comprising a nucleotide sequence encoding a heterologous gene of interest for use as a vaccine comprising the steps of inserting the heterologous gene of interest into the adenovirus genome by recombining terminal protein complexed adenovirus genomic DNA (TPC-Ad gDNA) with a polynucleotide comprising a nucleotide sequence encoding the gene of interest and having 5′ and 3′ ends that are homologous to the insertion site sequence of the adenovirus genomic DNA in an in vitro recombination reaction, transfecting cells growing in individual vessels with a dilution of the in vitro recombination reaction mixture from (i) such that a number of such individual vessels contain a single cell that is infected by a recombinant adenovirus comprising the nucleotide sequence encoding the heterologous gene of interest, and identifying those individual vessels in which a single cell has been infected by the recombinant adenovirus comprising the nucleotide sequence encoding the heterologous gene of interest. Suitably said TPC-Ad gDNA comprises serotype-matched terminal protein and adenovirus genome, and said gene of interest codes for a single epitope, a string of epitopes, a segment of an antigen or a complete antigen protein. The invention also relates to recombinant adenoviruses and compositions made using these methods.

A method for designing a protein capable of binding in a DNA base selective manner or DNA base sequence specific manner is provided. According to the present invention, it was revealed that, with a protein that can bind in a DNA base-selective manner or a DNA base sequence-specific manner, which contains one or more, preferably 2 to 30, more preferably 5 to 25, most preferably 9 to 15, of PPR motifs having a structure of the following formula 1 (wherein, in the formula 1, Helix A is a part that can form an α-helix structure; X does not exist, or is a part consisting of 1 to 9 amino acids; Helix B is a part that can form an α-helix structure; and L is a part consisting of 2 to 7 amino acids), and having a specific combination of amino acids corresponding to a DNA base or DNA base sequence as amino acids of three positions of No. 1 A.A., No. 4 A.A., in Helix A of the formula 1 and No. “ii” (-2) A.A. contained in L of the formula 1, the aforementioned object could be achieved.

(Helix A)-X-(Helix B)-L  (Formula 1)